Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Taysha Gene Therapies, Inc.
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
March 29, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
March 24, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
March 23, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
February 09, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
January 31, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis
January 27, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
January 03, 2022
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
December 28, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Added to the ICE Biotechnology Index
December 23, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
December 22, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
December 16, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
December 06, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
November 08, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
November 03, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
October 21, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence
October 13, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
October 12, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
September 29, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
September 28, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
September 22, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
September 15, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
September 08, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences
September 01, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
August 25, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
August 17, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
August 16, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
August 09, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
August 02, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Tickers
TSHA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.